Magenta Therapeutics nabs $52 mln Series C
Cambridge, Massachusetts-based Magenta Therapeutics, a biotechnology company focused on developing new medicines "to bring the curative power of bone marrow transplant to more patients," has closed $52 million in Series C financing. Casdin Capital led the round with participation from other investors that included EcoR1 Capital, Eventide Asset Management, Watermill Asset Management, Be the Match BioTherapies and Access Industries.
9 April 2018•1 min read
